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A supramolecular strategy to assemble multifunctional
viral nanoparticles†
Limin Chen,a Xia Zhao,a Yuan Lin,*a Yubin Huanga and Qian Wang*ab
Using a one-pot approach driven by the supramolecular interaction
between b-cyclodextrin and adamantyl moieties, multifunctional viral
nanoparticles can be facilely formulated for biomedical applications.
The development of multifunctional nanoparticles for biomedical
applications is of great importance.1,2 For example, the development
of theranostic nanoparticles loaded with therapeutic drugs and
imaging probes for the combined therapy and diagnosis has been
gaining wide interest.3,4 Recently, inspired by the hierarchical struc-
tures of biogenic viral particles, multifunctional virus-like nanostruc-
tures have been constructed from synthetic polymers.5,6 In the
meantime, the application of viral nanoparticles (VNPs) derived from
plants and bacteria in biomedical fields has also attracted great
attention, primarily due to their well-defined, programmable, multi-
valent and monodispersed structural features7–19 as well as their good
biocompatibility.20,21 To make the best use of the inherent composi-
tions and structures of VNPs, many multifunctional VNPs have been
constructed by the combination of mutagenesis and bioconjugation
approaches, by which a variety of targeting ligands, catalytic units,
diagnostic probes and therapeutic cargos have been anchored on the
surface or inside of the internal cavity of VNPs.12,22–29
On the other hand, supramolecular interactions have been
extensively applied to constructing drug and gene delivery systems,
as well as smart materials due to their modularity, reversibility and
stimuli-responsiveness.30–36 For example, b-cyclodextrin (b-CD), a
natural toroid-shaped cyclic oligosaccharide, is one of the most
widely used host-systems in supramolecular chemistry thanks to its
low cost, good water solubility and biocompatible properties.37
b-CD has a hydrophilic exterior surface and a hydrophobic interior
cavity that can accommodate a broad range of guest molecules
(e.g., adamantane, azobenzene, and ferrocene).38,39
In this work, the supramolecular interaction between b-CD
and adamantyl (Ada) moieties was exploited to assemble multi-
functional VNPs. Tobacco mosaic virus (TMV) was employed as a
model VNP, which is a classic example of rod-shaped plant virus,
300 nm long and 18 nm in diameter, consisting of 2130 identical
subunit proteins arranged helically around genomic single RNA
strand. b-CD units could be grafted onto the exterior surface of
TMV using efficient bioconjugation reactions; and folic acid (FA),
rhodamine B (RhB), doxorubicin (Dox), and polyethylene glycol
(PEG) (MW 2000 Da) were selected to functionalize TMV particles
upon derivatization with Ada moieties and sequential supra-
molecular assembly (Scheme 1).
As shown in Scheme 1A, b-CD was attached to the exterior
surface of TMV by sequential diazonium-coupling and CuI-catalyzed
azide–alkyne cycloaddition (CuAAC) reactions.40,41 b-CD-azide
was synthesized using a reported protocol,42 and the CuAAC
reaction was catalyzed with CuSO4 and sodium ascorbate (NaAsc).
43
Scheme 1 (A) Synthesis of TMV-b-CD by diazonium-coupling and CuAAC
reactions. (B) The structures of Ada derivatives. (C) Schematic demonstration of
the formation of multifunctional TMV via the supramolecular interaction
between b-CD and Ada moieties.
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The formation of TMV-Alkyne was confirmed by UV-Vis spectroscopy
(Fig. 1A) and MALDI-TOF MS (Fig. 1C). The UV-Vis spectrum of
TMV-b-CD shows a new absorption peak at 510 nm in company with
a significant decrease in absorbance at 330 nm compared to the
spectrum of TMV-Alkyne, which can be attributed to the conjugative
effect between the azobenzenyl and 1,2,3-triazol moieties, implying a
successful attachment of b-CD moieties by the CuAAC reaction. This
can also be verified by the SDS-PAGE analysis (Fig. 1B). The grafting
efficiency was roughly estimated to be about 50% based on band
density analysis of TMV-b-CD subunit proteins versus TMV-Alkyne
subunit proteins, indicating that every TMV particle has about 1000
b-CD units, which is consistent with the MALDI-TOF MS result
(Fig. 1C). Increasing the concentration of b-CD-azide did not
improve the grafting density, which saturated at B50% (Fig. S1,
ESI†). We hypothesize that the incomplete conjugation is due to the
steric hindrance of the b-CD moieties. Finally, the integrity of the
TMV particles upon conjugation was confirmed using transmission
electron microscopy (TEM, Fig. 1D).
To test the supramolecular interaction between b-CD and Ada
moieties, a series of Ada derivatives were synthesized by either
esterification or amidation reactions following literature protocols
(see ESI† for experimental details). As a typical protocol, TMV-b-CD
was incubated with a 10-fold molar excess of Ada-RhB relative
to the subunit proteins for 30 min at 4 1C, followed by dialysis
and ultracentrifugation affording TMV-b-CD/Ada-RhB, which
was confirmed by size-exclusion chromatography (SEC) analysis
(Fig. 2A). The SEC diagram shows that the retention volume of
TMV-b-CD/Ada-RhB is identical to that of TMV-b-CD; however, a
significantly enhanced absorbance at 568 nm is observed
due to the encapsulation with Ada-RhB. In comparison, the
control experiment following the identical protocol but using
unmodified TMV did not show any non-specific interactions
with Ada-RhB as confirmed by SEC analysis (Fig. S2A, ESI†). The
results validated that TMV-b-CD can assemble with Ada-RhB via
the interaction between b-CD and Ada groups.
The eluted TMV-b-CD/Ada-RhB fraction was subjected to UV-Vis
spectroscopy assay (Fig. 2B), and the labeling efficiency was calculated
based on typical absorbance of TMV-b-CD and Ada-RhB. The yield
was B100%, indicating that all b-CD units were quantitatively filled
with Ada moieties, i.e. each TMV-b-CD particle was complexed with
B1000 Ada-RhB molecules (see ESI† for details). Furthermore, the
integrity of TMV-b-CD/Ada-RhB was confirmed using TEM (Fig. S2B,
ESI†). It is noteworthy that the positively charged Ada-RhB did
not induce the aggregation and precipitation of TMV-b-CD
particles. Following the identical procedure, TMV-b-CD/
Ada-Dox (or Ada-FA, Ada-PEG-RhB) can be readily achieved
(Fig. S3–S5, ESI†). Each TMV-b-CD particle can accommodate
B1000 Ada-Dox and Ada-FA molecules but only B700 Ada-PEG-
RhB molecules due to the steric hindrance.
To test the one-pot co-assembly behavior between TMV-b-CD and
different Ada derivatives, TMV-b-CD/Ada-FA/Ada-RhB was prepared
following the typical protocol. The UV-Vis spectra show that the
absorbance of Ada-FA (l280nm) gradually increases in company with
the decrease in the absorbance of Ada-RhB (l568nm) as various molar
ratios of Ada-FA and Ada-RhB from 1 : 9 to 9 : 1 were used (Fig. 2C).
Based on the UV-Vis spectrum, the average number of Ada-FA and
Ada-RhB moieties per TMV-b-CD particle can be determined accord-
ingly (see ESI†), and the results are given in Fig. S6C, ESI.† According
to the TEM results (Fig. 1D and 2D), there were no significant
changes in length and diameter of TMV particles after being grafted
with b-CD and sequential assembly. TMV-b-CD/Ada-FA/Ada-Dox can
also be prepared following the same protocol (Fig. S6, ESI†).
In vitro drug release kinetics showed that Ada-Dox released in a
sustained manner due to the dissociation of the b-CD/Ada supramo-
lecular structure (Fig. S7, ESI†), similar to the literature reports.31,32,36
To investigate the selective targeting ability of Dox-loaded TMV,
HepG2 tumor cells (folate receptor positive) and NIH-3T3 fibroblast
Fig. 1 Characterization of TMV-b-CD. (A) UV-Vis spectra of TMV, TMV-Alkyne and
TMV-b-CD. (B) SDS-PAGE: lane 1, protein markers; lane 2, TMV; lane 3, TMV-Alkyne;
lane 4, TMV-b-CD (* indicates the TMV-b-CD capsid monomer). (C) MALDI-TOF MS of
the subunit proteins of TMV (m/z 17 534), TMV-Alkyne (m/z 17 662) and TMV-b-CD
(m/z 18 822, the 1160 m/z difference between TMV-b-CD and TMV-Alkyne is
consistent with the theoretical molar mass of newly added b-CD-azide). (D) TEM image
of uranyl acetate-stained TMV-b-CD. The scale bar is 200 nm.
Fig. 2 (A) SEC diagram of TMV-b-CD/Ada-RhB (red) and TMV-b-CD (black)
monitored at 260 nm (solid) and 568 nm (dot). (B) UV-Vis spectra of TMV-b-CD,
Ada-RhB and TMV-b-CD/Ada-RhB. (C) UV-Vis spectra of TMV-b-CD/Ada-FA/
Ada-RhB with varying molar ratios of Ada-FA and Ada-RhB (nAda-FA : nAda-RhB)
used. (D) TEM image of uranyl acetate-stained TMV-b-CD/Ada-FA/Ada-RhB
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cells (folate receptor negative) were treated with TMV-b-CD/
Ada-Dox, TMV-b-CD/Ada-FA/Ada-Dox and free Dox. Cellular uptake
and cell proliferation were evaluated by confocal laser scanning
microscopy and cell viability assay, respectively. As shown in Fig. 3
and Fig. S8 (ESI†), the two types of Dox-loaded TMV showed low red
fluorescence in NIH-3T3 cells, while TMV-b-CD/Ada-FA/Ada-Dox
showed much stronger red fluorescence in HepG2 cells compared
to TMV-b-CD/Ada-Dox. It indicated that the folate receptor-mediated
endocytosis enhanced the intracellular drug delivery. As shown in
Fig. S9 (ESI†), the two types of Dox-loaded TMV significantly
decreased the cytotoxicity of Dox against NIH-3T3 cells, while
TMV-b-CD/Ada-FA/Ada-Dox showed much higher cytotoxicity against
HepG2 cells than TMV-b-CD/Ada-Dox, which was comparable to that
of free Dox. It demonstrated that Dox-loaded TMV with the aid of FA
moieties showed noticeable antitumor selectivity compared to free
Dox. The TMV-b-CD/Ada-FA/Ada-Dox particles afforded comparable
therapy efficiency of free Dox towards HepG2 cells, confirming the
potential for sustained release of Dox due to the dissociation of the
b-CD/Ada supramolecular structure.31,32
In summary, we have demonstrated here a supramolecular
strategy based on the interaction between b-CD and Ada moieties.
Using this method, multifunctional TMV particles have been
constructed in a facile manner to load with imaging agents,
targeting ligands, and chemotherapeutic drugs, which could
potentially be used in therapeutic and diagnostic applications.
More importantly, based on this work, we expect that a broad
range of stimuli-responsive supramolecular interactions can be
combined with VNPs for versatile applications.
This work was supported by the National Natural Science
Foundation of China (21128002 and 21104080).
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Fig. 3 Fluorescent microscopy images of HepG2 cells. (A and B) HepG2 cells
incubated with TMV-b-CD/Ada-Dox and TMV-b-CD/Ada-FA/Ada-Dox for 24 h,
respectively. 1, 2 and 3 indicate the DAPI, Ada-Dox and merged channels,
respectively. The scale bars represent 50 mm.
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